PCSK9 association with lipoprotein(a)

Circulation Research

Volumn 119, Issue 1, 2016, Pages 29-35

  Tavori, Hagai ^a   Christian, Devon ^a   Minnier, Jessica ^b   Plubell, Deanna ^a   Shapiro, Michael D ^a   Yeang, Calvin ^c   Giunzioni, Ilaria ^a   Croyal, Mikael ^d   Duell, P Barton ^a   Lambert, Gilles ^d,e,f,g   Tsimikas, Sotirios ^c   Fazio, Sergio ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ DE NANTES   (France)

^e INSERM   (France)

^f UNIVERSITÉ DE LA RÉUNION   (France)

^g site Centre Hospitalier Félix Guyon   (France)

Author keywords

lipids and lipoprotein metabolism; lipoprotein(a); low density lipoprotein; proprotein convertase subtilisin Kexin type 9

Indexed keywords

APOLIPOPROTEIN B; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; UNCLASSIFIED DRUG; APOLIPOPROTEIN A; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; PROTEIN BINDING;

ADULT; AGED; APHERESIS; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; HUMAN; IMMUNOBLOTTING; IMMUNODETECTION; IMMUNOPRECIPITATION; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; ANIMAL; BLOOD; METABOLISM;

ANIMALS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; BIOMARKERS; HUMANS; LIPOPROTEIN(A); MICE; PROPROTEIN CONVERTASE 9; PROTEIN BINDING;

EID: 84964699793     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308811     Document Type: Article

References (34)

1. Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS, Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012 32 3058 3065. doi: 10.1161/ATVBAHA.112.255521
2. Holmes DT, Schick BA, Humphries KH, Frohlich J, Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005 51 2067 2073. doi: 10.1373/clinchem.2005.055228
3. Marcovina SM, Koschinsky ML, Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advanced atherosclerosis? Circulation 1999 100 1151 1153
4. Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL, Mauri M, Ordovás JM, Mata P, SAFEHEART Investigators Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014 63 1982 1989. doi: 10.1016/j.jacc.2014.01.063
5. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015 290 11649 11662. doi: 10.1074/jbc.M114.611988
6. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995 95 1403 1408. doi: 10.1172/JCI117794
7. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL, HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989 80 1313 1319
8. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ, Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005 46 2681 2691. doi: 10.1194/jlr.M500249-JLR200
9. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet 2015 385 341 350. doi: 10.1016/S0140-6736(14)61374-X
10. Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS, AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013 128 962 969. doi: 10.1161/CIRCULATIONAHA.113.001969
11. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL, Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015 386 1472 1483. doi: 10.1016/S0140-6736(15)61252-1
12. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003 100 928 933. doi: 10.1073/pnas.0335507100
13. Horton JD, Cohen JC, Hobbs HH, Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007 32 71 77. doi: 10.1016/j.tibs.2006.12.008
14. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB, Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012 32 1585 1595. doi: 10.1161/ATVBAHA.112.250043
15. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S, Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 2014 130 431 441. doi: 10.1161/CIRCULATIONAHA.113.006720
16. Raal F, Panz V, Immelman A, Pilcher G, Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013 2 e000028. doi: 10.1161/JAHA.112.000028
17. Ridker PM, Rifai N, Bradwin G, Rose L, Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J 2016 37 554 560. doi: 10.1093/eurheartj/ehv568
18. Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N, Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients. J Diabetes Complications 2015 29 1165 1170. doi: 10.1016/j.jdiacomp.2015.08.003
19. Therapeutic monoclonal antibodies approved or in review in the European Union or United States. The antibody society December 30, 2015
20. Stein EA, Raal FJ, Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation 2013 127 2372 2374. doi: 10.1161/CIRCULATIONAHA.113.003360
21. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA, Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014 114 711 715. doi: 10.1016/j.amjcard.2014.05.060
22. Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, Fazio S, Self-Association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008 47 1631 1639. doi: 10.1021/bi7016359
23. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S, Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013 127 2403 2413. doi: 10.1161/CIRCULATIONAHA.113.001592
24. Kosenko T, Golder M, Leblond G, Weng W, Lagace TA, Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 2013 288 8279 8288. doi: 10.1074/jbc.M112.421370
25. Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, Tsimikas S, Curtiss LK, Marcovina SM, Taylor JM, Lawn RM, Innerarity TL, Pitas RE, High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res 2005 46 769 778. doi: 10.1194/jlr.M400467-JLR200
26. Yeang C, Witztum JL, Tsimikas S, 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 2015 26 169 178. doi: 10.1097/MOL.0000000000000171
27. Yeang C, Choi Y, Lee S, Bertoia M, Rimm E, Yang X, Witztum J, Tsimikas S, Novel assays for quantification of lipoprotein-Associated (pcsk9-Apob, pcsk9-lp(a)) proprotein covertase subtilisin/kexin type 9 (pcks9). Circulation 2015 132 A14697
28. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG, The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006 281 30561 30572. doi: 10.1074/jbc.M606495200
29. Tavori H, Giunzioni I, Linton MF, Fazio S, Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res 2013 113 1290 1295. doi: 10.1161/CIRCRESAHA.113.302655
30. Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M, Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 (pcsk9) by low-density lipoprotein-Apheresis in familial hypercholesterolemia: Development and application of a new assay for pcsk9. J Clin Endocrinol Metab 2015 100 E41 E49. doi: 10.1210/jc.2014-3066
31. Maxwell KN, Breslow JL, Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004 101 7100 7105. doi: 10.1073/pnas.0402133101
32. Konrad RJ, Troutt JS, Cao G, Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis 2011 10 38. doi: 10.1186/1476-511X-10-38
33. Contois JH, Lammi-Keefe CJ, Vogel S, McNamara JR, Wilson PW, Massov T, Schaefer EJ, Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay. Clin Chim Acta 1996 253 21 35
34. Leander K, Mälarstig A, Van't Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A, De Faire U, Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation 2016 133 1230 1239. doi: 10.1161/CIRCULATIONAHA.115.018531